Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Mackay Shields LLC
01:02pm, Saturday, 07'th Mar 2020
Mackay Shields LLC lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
09:47pm, Friday, 06'th Mar 2020
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
Fmr LLC Trims Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
01:43pm, Friday, 06'th Mar 2020
Fmr LLC lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The f
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expected to Announce Earnings of -$0.01 Per Share
11:32am, Friday, 06'th Mar 2020
Wall Street analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will announce earnings per share of ($0.01) for the current fiscal quarter, Zacks reports. Three analysts have provided estim
